Skip to main content
Clinical Trials/NCT05983172
NCT05983172
Enrolling By Invitation
Not Applicable

Multi-omics Approach of Risk Stratification for Patients With de Novo Acute Myeloid Leukemia

National Taiwan University Hospital1 site in 1 country1,500 target enrollmentAugust 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Myeloid Leukemia
Sponsor
National Taiwan University Hospital
Enrollment
1500
Locations
1
Primary Endpoint
Overall survival
Status
Enrolling By Invitation
Last Updated
2 years ago

Overview

Brief Summary

The investigators will use machine learning to identify features on bone marrow smears and select features that are related to gene mutations, gene expression, or prognosis. The investigators will then use genome-wide transcriptomic profiling to investigate gene expression that is associated with patients' outcomes. The investigators will design a next-generation sequencing panel with unique molecular index and assess its feasibility and robustness in detecting measurable residual disease and optimize the panel/platform/bioinformatic pipeline. Finally, The investigators will use machine learning to integrate bone marrow smear features, gene mutations, gene expression, and measurable residual disease to construct a comprehensive risk assessment system that is based on multi-omics data. The investigators believe that such a platform will help physicians to design the most appropriate treatment strategies for individual patients, not only advancing the concept of precision medicine but also improving patients' prognoses.

Registry
clinicaltrials.gov
Start Date
August 2023
End Date
July 2026
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

National Taiwan University Clinical Trial Center

Assistant Professor and attending physician

National Taiwan University Hospital

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with acute myeloid leukemia at the National Taiwan University Hospital
  • Ever enrolled in 201802021RINC、202109078RINB、201709072RINC

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Overall survival

Time Frame: From date of diagnosis until the date of death from any cause, assessed up to 30 years

Study Sites (1)

Loading locations...

Similar Trials